Canada Markets open in 4 hrs 17 mins

Iterum Therapeutics plc (ITRM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2395+0.0210 (+9.61%)
At close: 04:00PM EDT
0.2202 -0.02 (-8.06%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.2185
Open0.2221
Bid0.0000 x 3000
Ask0.0000 x 1100
Day's Range0.2221 - 0.2395
52 Week Range0.1850 - 2.5200
Volume782,263
Avg. Volume1,181,391
Market Cap43.775M
Beta (5Y Monthly)1.07
PE Ratio (TTM)N/A
EPS (TTM)-0.7690
Earnings DateMar 10, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Iterum Therapeutics Reports First Quarter 2022 Financial Results

    -General Alignment with FDA on Key Aspects of Design of Proposed Additional Clinical Trial- -Cash Runway into 2024- DUBLIN, Ireland and CHICAGO, May 13, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March

  • GlobeNewswire

    Iterum Therapeutics Provides Regulatory Update

    DUBLIN, Ireland and CHICAGO, May 11, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced it met with the US Food and Drug Administration (“FDA”) on May 5, 2022, to discuss its proposed plan to conduct one additional Phase 3 clinical trial to support t

  • GlobeNewswire

    Iterum Therapeutics Presented Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases

    DUBLIN, Ireland and CHICAGO, April 25, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced two poster presentations at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 23-26, 2022 in Lisbon, Portugal.